Efficacy of neoadjuvant chemotherapy of modified FOLFOX7 regimen for advanced gastric cancer
10.3760/cma.j.issn.1673-9752.2009.06.008
- VernacularTitle:改良FOLFOX7方案新辅助化疗对进展期胃癌患者的疗效分析
- Author:
Jun ZHANG
;
Jing ZHANG
;
Hua MENG
;
Guocong WU
;
Jun CAI
;
Kangli WANG
;
Zhongtao ZHANG
;
Yu WANG
- Publication Type:Journal Article
- Keywords:
Gastric neoplasms;
Neoadjuvant chemotherapy;
FOLFOX7 regimen;
modified
- From:
Chinese Journal of Digestive Surgery
2009;8(6):416-418
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of neoadjuvant chemotherapy of modified FOLFOX7 regimen in the treatment of advanced gastric cancer. Methods The clinical data of 30 patients with advanced gastric cancer who had been admitted to Beijing Friendship Hospital from June 2005 to January 2009 were retrospectively analyzed. All patients received modified FOLFOX7 regimen [oxaliplatin (100 mg/m~2) + fluorouracil (2400 mg/m~2) + calcium folinate (400 mg/m~2)] for 2-4 courses before operation. The efficacy and toxicity of the modified FOLFOX7 were evaluated before and after the operation. All data were analyzed via chi-square test. Results The pre-and postoperative downstaging rates were 27% (8/30) and 47% (14/30), respectively. The total effective rate of modified FOLFOX7 regimen was 43% (13/30). Complete remission was observed in 1 patient. The toxicity was mild. Radical resection was accomplished in 28 patients (93%). There was no statistical difference between the 2 criteria in evaluating the efficacy of modified FOLFOX7 regimen (χ~2= 2.584, P>0.05). Conclusion Modified FOLFOX7 regimen is effective and well-tolerable for patients with advanced gastric cancer.
